Further studies are required to further inform its kinetics and prognostic utility, particularly in the setting of FLT3 inhibitors and R/R AML, and to predict those with emerging therapeutic resistance when treated with other novel therapeutics. Here, FLT3 is linked to acute myeloid leukemia.